nodes	percent_of_prediction	percent_of_DWPC	metapath
Methsuximide—Periorbital oedema—Sunitinib—pancreatic cancer	0.0411	0.0411	CcSEcCtD
Methsuximide—Gastrointestinal symptom NOS—Fluorouracil—pancreatic cancer	0.0218	0.0218	CcSEcCtD
Methsuximide—Proteinuria—Erlotinib—pancreatic cancer	0.0213	0.0214	CcSEcCtD
Methsuximide—Protein urine present—Erlotinib—pancreatic cancer	0.021	0.0211	CcSEcCtD
Methsuximide—Proteinuria—Sunitinib—pancreatic cancer	0.0185	0.0185	CcSEcCtD
Methsuximide—Protein urine present—Sunitinib—pancreatic cancer	0.0182	0.0183	CcSEcCtD
Methsuximide—Proteinuria—Gemcitabine—pancreatic cancer	0.0148	0.0149	CcSEcCtD
Methsuximide—Protein urine present—Gemcitabine—pancreatic cancer	0.0146	0.0146	CcSEcCtD
Methsuximide—Hiccups—Irinotecan—pancreatic cancer	0.0134	0.0134	CcSEcCtD
Methsuximide—Photophobia—Fluorouracil—pancreatic cancer	0.012	0.012	CcSEcCtD
Methsuximide—Pancytopenia—Tamoxifen—pancreatic cancer	0.0113	0.0113	CcSEcCtD
Methsuximide—Weight decreased—Tamoxifen—pancreatic cancer	0.0108	0.0108	CcSEcCtD
Methsuximide—Weight decreased—Erlotinib—pancreatic cancer	0.0106	0.0107	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Tamoxifen—pancreatic cancer	0.0105	0.0105	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Erlotinib—pancreatic cancer	0.0104	0.0104	CcSEcCtD
Methsuximide—Pancytopenia—Sunitinib—pancreatic cancer	0.00967	0.00969	CcSEcCtD
Methsuximide—Weight decreased—Sunitinib—pancreatic cancer	0.00921	0.00923	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Sunitinib—pancreatic cancer	0.009	0.00902	CcSEcCtD
Methsuximide—Erythema multiforme—Tamoxifen—pancreatic cancer	0.009	0.00902	CcSEcCtD
Methsuximide—Erythema multiforme—Erlotinib—pancreatic cancer	0.0089	0.00892	CcSEcCtD
Methsuximide—Irritability—Fluorouracil—pancreatic cancer	0.00887	0.00889	CcSEcCtD
Methsuximide—Ataxia—Fluorouracil—pancreatic cancer	0.00874	0.00876	CcSEcCtD
Methsuximide—Eosinophilia—Fluorouracil—pancreatic cancer	0.00796	0.00797	CcSEcCtD
Methsuximide—Pancytopenia—Gemcitabine—pancreatic cancer	0.00776	0.00778	CcSEcCtD
Methsuximide—Erythema multiforme—Sunitinib—pancreatic cancer	0.00771	0.00772	CcSEcCtD
Methsuximide—Pancytopenia—Fluorouracil—pancreatic cancer	0.00763	0.00764	CcSEcCtD
Methsuximide—Weight decreased—Irinotecan—pancreatic cancer	0.00759	0.0076	CcSEcCtD
Methsuximide—Leukopenia—Tamoxifen—pancreatic cancer	0.00742	0.00743	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Gemcitabine—pancreatic cancer	0.00722	0.00724	CcSEcCtD
Methsuximide—Haematuria—Gemcitabine—pancreatic cancer	0.00695	0.00696	CcSEcCtD
Methsuximide—Anorexia—Tamoxifen—pancreatic cancer	0.00645	0.00646	CcSEcCtD
Methsuximide—Anorexia—Erlotinib—pancreatic cancer	0.00638	0.00639	CcSEcCtD
Methsuximide—Leukopenia—Sunitinib—pancreatic cancer	0.00635	0.00636	CcSEcCtD
Methsuximide—Ataxia—Docetaxel—pancreatic cancer	0.00631	0.00632	CcSEcCtD
Methsuximide—Hiccups—Epirubicin—pancreatic cancer	0.00623	0.00625	CcSEcCtD
Methsuximide—Erythema multiforme—Gemcitabine—pancreatic cancer	0.00618	0.0062	CcSEcCtD
Methsuximide—Insomnia—Tamoxifen—pancreatic cancer	0.00612	0.00613	CcSEcCtD
Methsuximide—Insomnia—Erlotinib—pancreatic cancer	0.00605	0.00606	CcSEcCtD
Methsuximide—Decreased appetite—Tamoxifen—pancreatic cancer	0.00588	0.00589	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00584	0.00585	CcSEcCtD
Methsuximide—Decreased appetite—Erlotinib—pancreatic cancer	0.00582	0.00583	CcSEcCtD
Methsuximide—Constipation—Tamoxifen—pancreatic cancer	0.00578	0.00579	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00578	0.00579	CcSEcCtD
Methsuximide—Hiccups—Doxorubicin—pancreatic cancer	0.00577	0.00578	CcSEcCtD
Methsuximide—Constipation—Erlotinib—pancreatic cancer	0.00572	0.00573	CcSEcCtD
Methsuximide—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00553	0.00554	CcSEcCtD
Methsuximide—Anorexia—Sunitinib—pancreatic cancer	0.00552	0.00553	CcSEcCtD
Methsuximide—Pancytopenia—Docetaxel—pancreatic cancer	0.00551	0.00552	CcSEcCtD
Methsuximide—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00547	0.00548	CcSEcCtD
Methsuximide—Urticaria—Tamoxifen—pancreatic cancer	0.00537	0.00538	CcSEcCtD
Methsuximide—Abdominal pain—Tamoxifen—pancreatic cancer	0.00535	0.00536	CcSEcCtD
Methsuximide—Abdominal pain—Erlotinib—pancreatic cancer	0.00529	0.0053	CcSEcCtD
Methsuximide—Vision blurred—Fluorouracil—pancreatic cancer	0.00528	0.00529	CcSEcCtD
Methsuximide—Weight decreased—Docetaxel—pancreatic cancer	0.00525	0.00526	CcSEcCtD
Methsuximide—Insomnia—Sunitinib—pancreatic cancer	0.00524	0.00525	CcSEcCtD
Methsuximide—Leukopenia—Irinotecan—pancreatic cancer	0.00523	0.00524	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.00513	0.00514	CcSEcCtD
Methsuximide—Leukopenia—Gemcitabine—pancreatic cancer	0.0051	0.00511	CcSEcCtD
Methsuximide—Decreased appetite—Sunitinib—pancreatic cancer	0.00503	0.00504	CcSEcCtD
Methsuximide—Leukopenia—Fluorouracil—pancreatic cancer	0.00501	0.00502	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.005	0.00501	CcSEcCtD
Methsuximide—Constipation—Sunitinib—pancreatic cancer	0.00495	0.00496	CcSEcCtD
Methsuximide—Confusional state—Irinotecan—pancreatic cancer	0.00481	0.00482	CcSEcCtD
Methsuximide—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00474	0.00474	CcSEcCtD
Methsuximide—Diarrhoea—Tamoxifen—pancreatic cancer	0.00463	0.00464	CcSEcCtD
Methsuximide—Confusional state—Fluorouracil—pancreatic cancer	0.00461	0.00462	CcSEcCtD
Methsuximide—Abdominal pain—Sunitinib—pancreatic cancer	0.00458	0.00459	CcSEcCtD
Methsuximide—Diarrhoea—Erlotinib—pancreatic cancer	0.00458	0.00459	CcSEcCtD
Methsuximide—Anorexia—Irinotecan—pancreatic cancer	0.00455	0.00456	CcSEcCtD
Methsuximide—Dizziness—Tamoxifen—pancreatic cancer	0.00447	0.00448	CcSEcCtD
Methsuximide—Anorexia—Gemcitabine—pancreatic cancer	0.00443	0.00444	CcSEcCtD
Methsuximide—Dizziness—Erlotinib—pancreatic cancer	0.00442	0.00443	CcSEcCtD
Methsuximide—Erythema multiforme—Docetaxel—pancreatic cancer	0.00439	0.0044	CcSEcCtD
Methsuximide—Anorexia—Fluorouracil—pancreatic cancer	0.00436	0.00436	CcSEcCtD
Methsuximide—Insomnia—Irinotecan—pancreatic cancer	0.00431	0.00432	CcSEcCtD
Methsuximide—Vomiting—Tamoxifen—pancreatic cancer	0.0043	0.00431	CcSEcCtD
Methsuximide—Rash—Tamoxifen—pancreatic cancer	0.00426	0.00427	CcSEcCtD
Methsuximide—Dermatitis—Tamoxifen—pancreatic cancer	0.00426	0.00427	CcSEcCtD
Methsuximide—Ataxia—Epirubicin—pancreatic cancer	0.00426	0.00426	CcSEcCtD
Methsuximide—Vomiting—Erlotinib—pancreatic cancer	0.00425	0.00426	CcSEcCtD
Methsuximide—Somnolence—Irinotecan—pancreatic cancer	0.00424	0.00425	CcSEcCtD
Methsuximide—Headache—Tamoxifen—pancreatic cancer	0.00424	0.00424	CcSEcCtD
Methsuximide—Rash—Erlotinib—pancreatic cancer	0.00422	0.00423	CcSEcCtD
Methsuximide—Dermatitis—Erlotinib—pancreatic cancer	0.00421	0.00422	CcSEcCtD
Methsuximide—Insomnia—Gemcitabine—pancreatic cancer	0.0042	0.00421	CcSEcCtD
Methsuximide—Headache—Erlotinib—pancreatic cancer	0.00419	0.0042	CcSEcCtD
Methsuximide—Decreased appetite—Irinotecan—pancreatic cancer	0.00415	0.00415	CcSEcCtD
Methsuximide—Insomnia—Fluorouracil—pancreatic cancer	0.00413	0.00414	CcSEcCtD
Methsuximide—Somnolence—Gemcitabine—pancreatic cancer	0.00413	0.00414	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00412	0.00413	CcSEcCtD
Methsuximide—Constipation—Irinotecan—pancreatic cancer	0.00408	0.00409	CcSEcCtD
Methsuximide—Somnolence—Fluorouracil—pancreatic cancer	0.00406	0.00407	CcSEcCtD
Methsuximide—Decreased appetite—Gemcitabine—pancreatic cancer	0.00404	0.00405	CcSEcCtD
Methsuximide—Nausea—Tamoxifen—pancreatic cancer	0.00402	0.00402	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00401	0.00402	CcSEcCtD
Methsuximide—Constipation—Gemcitabine—pancreatic cancer	0.00397	0.00398	CcSEcCtD
Methsuximide—Nausea—Erlotinib—pancreatic cancer	0.00397	0.00398	CcSEcCtD
Methsuximide—Decreased appetite—Fluorouracil—pancreatic cancer	0.00397	0.00398	CcSEcCtD
Methsuximide—Diarrhoea—Sunitinib—pancreatic cancer	0.00396	0.00397	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00394	0.00395	CcSEcCtD
Methsuximide—Ataxia—Doxorubicin—pancreatic cancer	0.00394	0.00394	CcSEcCtD
Methsuximide—Feeling abnormal—Irinotecan—pancreatic cancer	0.00393	0.00394	CcSEcCtD
Methsuximide—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.0039	0.00391	CcSEcCtD
Methsuximide—Eosinophilia—Epirubicin—pancreatic cancer	0.00387	0.00388	CcSEcCtD
Methsuximide—Dizziness—Sunitinib—pancreatic cancer	0.00383	0.00384	CcSEcCtD
Methsuximide—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00383	0.00384	CcSEcCtD
Methsuximide—Abdominal pain—Irinotecan—pancreatic cancer	0.00377	0.00378	CcSEcCtD
Methsuximide—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00377	0.00377	CcSEcCtD
Methsuximide—Pancytopenia—Epirubicin—pancreatic cancer	0.00371	0.00372	CcSEcCtD
Methsuximide—Vomiting—Sunitinib—pancreatic cancer	0.00368	0.00369	CcSEcCtD
Methsuximide—Rash—Sunitinib—pancreatic cancer	0.00365	0.00366	CcSEcCtD
Methsuximide—Dermatitis—Sunitinib—pancreatic cancer	0.00365	0.00366	CcSEcCtD
Methsuximide—Urticaria—Fluorouracil—pancreatic cancer	0.00363	0.00364	CcSEcCtD
Methsuximide—Headache—Sunitinib—pancreatic cancer	0.00363	0.00364	CcSEcCtD
Methsuximide—Leukopenia—Docetaxel—pancreatic cancer	0.00362	0.00362	CcSEcCtD
Methsuximide—Eosinophilia—Doxorubicin—pancreatic cancer	0.00358	0.00359	CcSEcCtD
Methsuximide—Weight decreased—Epirubicin—pancreatic cancer	0.00354	0.00355	CcSEcCtD
Methsuximide—Drowsiness—Epirubicin—pancreatic cancer	0.00349	0.00349	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.00346	0.00346	CcSEcCtD
Methsuximide—Nausea—Sunitinib—pancreatic cancer	0.00344	0.00345	CcSEcCtD
Methsuximide—Pancytopenia—Doxorubicin—pancreatic cancer	0.00344	0.00344	CcSEcCtD
Methsuximide—Haematuria—Epirubicin—pancreatic cancer	0.00333	0.00333	CcSEcCtD
Methsuximide—Confusional state—Docetaxel—pancreatic cancer	0.00333	0.00333	CcSEcCtD
Methsuximide—Weight decreased—Doxorubicin—pancreatic cancer	0.00327	0.00328	CcSEcCtD
Methsuximide—Diarrhoea—Irinotecan—pancreatic cancer	0.00326	0.00327	CcSEcCtD
Methsuximide—Drowsiness—Doxorubicin—pancreatic cancer	0.00323	0.00323	CcSEcCtD
Methsuximide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.0032	0.00321	CcSEcCtD
Methsuximide—Diarrhoea—Gemcitabine—pancreatic cancer	0.00318	0.00319	CcSEcCtD
Methsuximide—Dizziness—Irinotecan—pancreatic cancer	0.00315	0.00316	CcSEcCtD
Methsuximide—Anorexia—Docetaxel—pancreatic cancer	0.00314	0.00315	CcSEcCtD
Methsuximide—Diarrhoea—Fluorouracil—pancreatic cancer	0.00313	0.00313	CcSEcCtD
Methsuximide—Haematuria—Doxorubicin—pancreatic cancer	0.00308	0.00308	CcSEcCtD
Methsuximide—Vomiting—Irinotecan—pancreatic cancer	0.00303	0.00304	CcSEcCtD
Methsuximide—Dizziness—Fluorouracil—pancreatic cancer	0.00302	0.00303	CcSEcCtD
Methsuximide—Rash—Irinotecan—pancreatic cancer	0.00301	0.00301	CcSEcCtD
Methsuximide—Dermatitis—Irinotecan—pancreatic cancer	0.00301	0.00301	CcSEcCtD
Methsuximide—Headache—Irinotecan—pancreatic cancer	0.00299	0.00299	CcSEcCtD
Methsuximide—Insomnia—Docetaxel—pancreatic cancer	0.00298	0.00299	CcSEcCtD
Methsuximide—Erythema multiforme—Epirubicin—pancreatic cancer	0.00296	0.00297	CcSEcCtD
Methsuximide—Vomiting—Gemcitabine—pancreatic cancer	0.00295	0.00296	CcSEcCtD
Methsuximide—Somnolence—Docetaxel—pancreatic cancer	0.00293	0.00294	CcSEcCtD
Methsuximide—Rash—Gemcitabine—pancreatic cancer	0.00293	0.00294	CcSEcCtD
Methsuximide—Dermatitis—Gemcitabine—pancreatic cancer	0.00293	0.00293	CcSEcCtD
Methsuximide—Headache—Gemcitabine—pancreatic cancer	0.00291	0.00292	CcSEcCtD
Methsuximide—Vomiting—Fluorouracil—pancreatic cancer	0.00291	0.00291	CcSEcCtD
Methsuximide—Rash—Fluorouracil—pancreatic cancer	0.00288	0.00289	CcSEcCtD
Methsuximide—Dermatitis—Fluorouracil—pancreatic cancer	0.00288	0.00288	CcSEcCtD
Methsuximide—Decreased appetite—Docetaxel—pancreatic cancer	0.00287	0.00287	CcSEcCtD
Methsuximide—Headache—Fluorouracil—pancreatic cancer	0.00286	0.00287	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00285	0.00285	CcSEcCtD
Methsuximide—Nausea—Irinotecan—pancreatic cancer	0.00283	0.00284	CcSEcCtD
Methsuximide—Constipation—Docetaxel—pancreatic cancer	0.00282	0.00283	CcSEcCtD
Methsuximide—Nausea—Gemcitabine—pancreatic cancer	0.00276	0.00277	CcSEcCtD
Methsuximide—Erythema multiforme—Doxorubicin—pancreatic cancer	0.00274	0.00274	CcSEcCtD
Methsuximide—Feeling abnormal—Docetaxel—pancreatic cancer	0.00272	0.00272	CcSEcCtD
Methsuximide—Nausea—Fluorouracil—pancreatic cancer	0.00271	0.00272	CcSEcCtD
Methsuximide—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.0027	0.0027	CcSEcCtD
Methsuximide—Tension—Epirubicin—pancreatic cancer	0.00267	0.00268	CcSEcCtD
Methsuximide—Nervousness—Epirubicin—pancreatic cancer	0.00265	0.00265	CcSEcCtD
Methsuximide—Abdominal pain—Docetaxel—pancreatic cancer	0.00261	0.00261	CcSEcCtD
Methsuximide—Vision blurred—Epirubicin—pancreatic cancer	0.00257	0.00257	CcSEcCtD
Methsuximide—Tension—Doxorubicin—pancreatic cancer	0.00247	0.00248	CcSEcCtD
Methsuximide—Nervousness—Doxorubicin—pancreatic cancer	0.00245	0.00245	CcSEcCtD
Methsuximide—Leukopenia—Epirubicin—pancreatic cancer	0.00244	0.00244	CcSEcCtD
Methsuximide—Vision blurred—Doxorubicin—pancreatic cancer	0.00238	0.00238	CcSEcCtD
Methsuximide—Leukopenia—Doxorubicin—pancreatic cancer	0.00226	0.00226	CcSEcCtD
Methsuximide—Diarrhoea—Docetaxel—pancreatic cancer	0.00226	0.00226	CcSEcCtD
Methsuximide—Confusional state—Epirubicin—pancreatic cancer	0.00224	0.00225	CcSEcCtD
Methsuximide—Dizziness—Docetaxel—pancreatic cancer	0.00218	0.00218	CcSEcCtD
Methsuximide—Anorexia—Epirubicin—pancreatic cancer	0.00212	0.00212	CcSEcCtD
Methsuximide—Vomiting—Docetaxel—pancreatic cancer	0.0021	0.0021	CcSEcCtD
Methsuximide—Rash—Docetaxel—pancreatic cancer	0.00208	0.00208	CcSEcCtD
Methsuximide—Dermatitis—Docetaxel—pancreatic cancer	0.00208	0.00208	CcSEcCtD
Methsuximide—Confusional state—Doxorubicin—pancreatic cancer	0.00208	0.00208	CcSEcCtD
Methsuximide—Headache—Docetaxel—pancreatic cancer	0.00207	0.00207	CcSEcCtD
Methsuximide—Insomnia—Epirubicin—pancreatic cancer	0.00201	0.00202	CcSEcCtD
Methsuximide—Somnolence—Epirubicin—pancreatic cancer	0.00198	0.00198	CcSEcCtD
Methsuximide—Anorexia—Doxorubicin—pancreatic cancer	0.00196	0.00197	CcSEcCtD
Methsuximide—Nausea—Docetaxel—pancreatic cancer	0.00196	0.00196	CcSEcCtD
Methsuximide—Decreased appetite—Epirubicin—pancreatic cancer	0.00193	0.00194	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.00192	0.00192	CcSEcCtD
Methsuximide—Constipation—Epirubicin—pancreatic cancer	0.0019	0.00191	CcSEcCtD
Methsuximide—Insomnia—Doxorubicin—pancreatic cancer	0.00186	0.00187	CcSEcCtD
Methsuximide—Feeling abnormal—Epirubicin—pancreatic cancer	0.00183	0.00184	CcSEcCtD
Methsuximide—Somnolence—Doxorubicin—pancreatic cancer	0.00183	0.00183	CcSEcCtD
Methsuximide—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.00182	0.00182	CcSEcCtD
Methsuximide—Decreased appetite—Doxorubicin—pancreatic cancer	0.00179	0.00179	CcSEcCtD
Methsuximide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.00178	0.00178	CcSEcCtD
Methsuximide—Urticaria—Epirubicin—pancreatic cancer	0.00177	0.00177	CcSEcCtD
Methsuximide—Constipation—Doxorubicin—pancreatic cancer	0.00176	0.00176	CcSEcCtD
Methsuximide—Abdominal pain—Epirubicin—pancreatic cancer	0.00176	0.00176	CcSEcCtD
Methsuximide—Feeling abnormal—Doxorubicin—pancreatic cancer	0.0017	0.0017	CcSEcCtD
Methsuximide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.00168	0.00169	CcSEcCtD
Methsuximide—Urticaria—Doxorubicin—pancreatic cancer	0.00164	0.00164	CcSEcCtD
Methsuximide—Abdominal pain—Doxorubicin—pancreatic cancer	0.00163	0.00163	CcSEcCtD
Methsuximide—Diarrhoea—Epirubicin—pancreatic cancer	0.00152	0.00152	CcSEcCtD
Methsuximide—Dizziness—Epirubicin—pancreatic cancer	0.00147	0.00147	CcSEcCtD
Methsuximide—Vomiting—Epirubicin—pancreatic cancer	0.00141	0.00142	CcSEcCtD
Methsuximide—Diarrhoea—Doxorubicin—pancreatic cancer	0.00141	0.00141	CcSEcCtD
Methsuximide—Rash—Epirubicin—pancreatic cancer	0.0014	0.00141	CcSEcCtD
Methsuximide—Dermatitis—Epirubicin—pancreatic cancer	0.0014	0.0014	CcSEcCtD
Methsuximide—Headache—Epirubicin—pancreatic cancer	0.00139	0.0014	CcSEcCtD
Methsuximide—Dizziness—Doxorubicin—pancreatic cancer	0.00136	0.00136	CcSEcCtD
Methsuximide—Nausea—Epirubicin—pancreatic cancer	0.00132	0.00132	CcSEcCtD
Methsuximide—Vomiting—Doxorubicin—pancreatic cancer	0.00131	0.00131	CcSEcCtD
Methsuximide—Rash—Doxorubicin—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Methsuximide—Dermatitis—Doxorubicin—pancreatic cancer	0.0013	0.0013	CcSEcCtD
Methsuximide—Headache—Doxorubicin—pancreatic cancer	0.00129	0.00129	CcSEcCtD
Methsuximide—Nausea—Doxorubicin—pancreatic cancer	0.00122	0.00122	CcSEcCtD
Methsuximide—CACNA1I—Axon guidance—NRP1—pancreatic cancer	4.28e-05	0.0228	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NR5A2—pancreatic cancer	4.14e-05	0.0221	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—ACVR1B—pancreatic cancer	4.14e-05	0.0221	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—pancreatic cancer	3.91e-05	0.0208	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PDX1—pancreatic cancer	3.75e-05	0.02	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRP1—pancreatic cancer	3.16e-05	0.0168	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—SRC—pancreatic cancer	3.13e-05	0.0167	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRP1—pancreatic cancer	3.06e-05	0.0163	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRP1—pancreatic cancer	3.06e-05	0.0163	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NR5A2—pancreatic cancer	3.06e-05	0.0163	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—ACVR1B—pancreatic cancer	3.06e-05	0.0163	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—pancreatic cancer	3.03e-05	0.0162	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—NRAS—pancreatic cancer	3.01e-05	0.016	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NR5A2—pancreatic cancer	2.96e-05	0.0158	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—ACVR1B—pancreatic cancer	2.96e-05	0.0158	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—NFKBIA—pancreatic cancer	2.95e-05	0.0157	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—pancreatic cancer	2.92e-05	0.0156	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—PDX1—pancreatic cancer	2.76e-05	0.0147	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PDX1—pancreatic cancer	2.68e-05	0.0143	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—pancreatic cancer	2.68e-05	0.0143	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—KRAS—pancreatic cancer	2.59e-05	0.0138	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—pancreatic cancer	2.43e-05	0.0129	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SLC2A2—pancreatic cancer	2.36e-05	0.0126	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—SRC—pancreatic cancer	2.3e-05	0.0123	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—pancreatic cancer	2.26e-05	0.012	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NRP1—pancreatic cancer	2.25e-05	0.012	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—IAPP—pancreatic cancer	2.24e-05	0.0119	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—pancreatic cancer	2.24e-05	0.0119	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—SRC—pancreatic cancer	2.23e-05	0.0119	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—NRAS—pancreatic cancer	2.22e-05	0.0118	CbGpPWpGaD
Methsuximide—CACNA1I—NCAM signaling for neurite out-growth—HRAS—pancreatic cancer	2.2e-05	0.0117	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—pancreatic cancer	2.19e-05	0.0117	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRP1—pancreatic cancer	2.18e-05	0.0116	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—NRAS—pancreatic cancer	2.15e-05	0.0114	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CXCL8—pancreatic cancer	2.1e-05	0.0112	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CASP3—pancreatic cancer	2.01e-05	0.0107	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—CTNNB1—pancreatic cancer	1.94e-05	0.0103	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—KRAS—pancreatic cancer	1.91e-05	0.0102	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—KRAS—pancreatic cancer	1.85e-05	0.00985	CbGpPWpGaD
Methsuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—pancreatic cancer	1.81e-05	0.00966	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SLC2A2—pancreatic cancer	1.74e-05	0.00928	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SLC2A2—pancreatic cancer	1.69e-05	0.00899	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—IAPP—pancreatic cancer	1.65e-05	0.00881	CbGpPWpGaD
Methsuximide—CYP2C19—Melatonin metabolism and effects—APOE—pancreatic cancer	1.65e-05	0.00879	CbGpPWpGaD
Methsuximide—CACNA1G—NCAM signaling for neurite out-growth—HRAS—pancreatic cancer	1.62e-05	0.00864	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—IAPP—pancreatic cancer	1.6e-05	0.00853	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KDR—pancreatic cancer	1.58e-05	0.00844	CbGpPWpGaD
Methsuximide—CACNA1H—NCAM signaling for neurite out-growth—HRAS—pancreatic cancer	1.57e-05	0.00837	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—TGFB1—pancreatic cancer	1.57e-05	0.00835	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MET—pancreatic cancer	1.55e-05	0.00826	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SMAD4—pancreatic cancer	1.45e-05	0.0077	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HES1—pancreatic cancer	1.41e-05	0.00752	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MMP2—pancreatic cancer	1.29e-05	0.00689	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KDR—pancreatic cancer	1.17e-05	0.00622	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MET—pancreatic cancer	1.14e-05	0.00609	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KDR—pancreatic cancer	1.13e-05	0.00603	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KDR—pancreatic cancer	1.13e-05	0.00603	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MET—pancreatic cancer	1.11e-05	0.0059	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MET—pancreatic cancer	1.11e-05	0.0059	CbGpPWpGaD
Methsuximide—CACNA1H—Corticotropin-releasing hormone—AKT1—pancreatic cancer	1.09e-05	0.0058	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SMAD4—pancreatic cancer	1.07e-05	0.00568	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NOTCH1—pancreatic cancer	1.07e-05	0.00568	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HES1—pancreatic cancer	1.04e-05	0.00554	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SMAD4—pancreatic cancer	1.03e-05	0.0055	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HES1—pancreatic cancer	1.01e-05	0.00537	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—PPARG—pancreatic cancer	1.01e-05	0.00536	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—MMP9—pancreatic cancer	9.72e-06	0.00518	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP2—pancreatic cancer	9.54e-06	0.00508	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP2—pancreatic cancer	9.24e-06	0.00492	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP2—pancreatic cancer	9.23e-06	0.00492	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—SRC—pancreatic cancer	8.96e-06	0.00478	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—VEGFA—pancreatic cancer	8.73e-06	0.00465	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—NRAS—pancreatic cancer	8.62e-06	0.00459	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KDR—pancreatic cancer	8.34e-06	0.00444	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MET—pancreatic cancer	8.16e-06	0.00435	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KDR—pancreatic cancer	8.08e-06	0.0043	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MET—pancreatic cancer	7.9e-06	0.00421	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—EGFR—pancreatic cancer	7.86e-06	0.00419	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NOTCH1—pancreatic cancer	7.85e-06	0.00418	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NOTCH1—pancreatic cancer	7.61e-06	0.00405	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—KRAS—pancreatic cancer	7.42e-06	0.00395	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—PPARG—pancreatic cancer	7.41e-06	0.00395	CbGpPWpGaD
Methsuximide—CYP2C19—Arachidonic acid metabolism—PTGS2—pancreatic cancer	7.31e-06	0.00389	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—PPARG—pancreatic cancer	7.18e-06	0.00382	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—MMP9—pancreatic cancer	7.17e-06	0.00382	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—CTNNB1—pancreatic cancer	7.08e-06	0.00377	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—MMP9—pancreatic cancer	6.94e-06	0.0037	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—MMP9—pancreatic cancer	6.94e-06	0.0037	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP2—pancreatic cancer	6.81e-06	0.00363	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—SRC—pancreatic cancer	6.61e-06	0.00352	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP2—pancreatic cancer	6.59e-06	0.00351	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—VEGFA—pancreatic cancer	6.44e-06	0.00343	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—SRC—pancreatic cancer	6.4e-06	0.00341	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—SRC—pancreatic cancer	6.4e-06	0.00341	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—NRAS—pancreatic cancer	6.36e-06	0.00339	CbGpPWpGaD
Methsuximide—CACNA1I—Axon guidance—HRAS—pancreatic cancer	6.31e-06	0.00336	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—VEGFA—pancreatic cancer	6.23e-06	0.00332	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—VEGFA—pancreatic cancer	6.23e-06	0.00332	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—STAT3—pancreatic cancer	6.17e-06	0.00329	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—NRAS—pancreatic cancer	6.16e-06	0.00328	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—NRAS—pancreatic cancer	6.15e-06	0.00328	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—EGFR—pancreatic cancer	5.79e-06	0.00309	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TGFB1—pancreatic cancer	5.72e-06	0.00305	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—EGFR—pancreatic cancer	5.61e-06	0.00299	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—EGFR—pancreatic cancer	5.61e-06	0.00299	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—KRAS—pancreatic cancer	5.47e-06	0.00292	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—TNF—pancreatic cancer	5.34e-06	0.00284	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—KRAS—pancreatic cancer	5.3e-06	0.00282	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—KRAS—pancreatic cancer	5.3e-06	0.00282	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—CTNNB1—pancreatic cancer	5.22e-06	0.00278	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—MMP9—pancreatic cancer	5.12e-06	0.00273	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—CTNNB1—pancreatic cancer	5.05e-06	0.00269	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—MMP9—pancreatic cancer	4.95e-06	0.00264	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—SRC—pancreatic cancer	4.72e-06	0.00251	CbGpPWpGaD
Methsuximide—CACNA1G—Axon guidance—HRAS—pancreatic cancer	4.65e-06	0.00248	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—VEGFA—pancreatic cancer	4.59e-06	0.00245	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—SRC—pancreatic cancer	4.57e-06	0.00243	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—STAT3—pancreatic cancer	4.55e-06	0.00242	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—NRAS—pancreatic cancer	4.54e-06	0.00242	CbGpPWpGaD
Methsuximide—CACNA1H—Axon guidance—HRAS—pancreatic cancer	4.51e-06	0.0024	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—HRAS—pancreatic cancer	4.5e-06	0.0024	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—VEGFA—pancreatic cancer	4.45e-06	0.00237	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—STAT3—pancreatic cancer	4.41e-06	0.00235	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—NRAS—pancreatic cancer	4.39e-06	0.00234	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TGFB1—pancreatic cancer	4.22e-06	0.00225	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—EGFR—pancreatic cancer	4.13e-06	0.0022	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TGFB1—pancreatic cancer	4.08e-06	0.00218	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—EGFR—pancreatic cancer	4e-06	0.00213	CbGpPWpGaD
Methsuximide—CACNA1I—Developmental Biology—AKT1—pancreatic cancer	3.98e-06	0.00212	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—TNF—pancreatic cancer	3.94e-06	0.0021	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—KRAS—pancreatic cancer	3.91e-06	0.00208	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—TNF—pancreatic cancer	3.81e-06	0.00203	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—KRAS—pancreatic cancer	3.78e-06	0.00201	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—HRAS—pancreatic cancer	3.32e-06	0.00177	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—HRAS—pancreatic cancer	3.21e-06	0.00171	CbGpPWpGaD
Methsuximide—CACNA1G—Developmental Biology—AKT1—pancreatic cancer	2.93e-06	0.00156	CbGpPWpGaD
Methsuximide—CACNA1H—Developmental Biology—AKT1—pancreatic cancer	2.84e-06	0.00151	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PRSS1—pancreatic cancer	2.44e-06	0.0013	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—ARG2—pancreatic cancer	2.11e-06	0.00113	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TYMP—pancreatic cancer	1.85e-06	0.000985	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.52e-06	0.000812	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GLP1R—pancreatic cancer	1.49e-06	0.000794	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—DPYD—pancreatic cancer	1.47e-06	0.000781	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	1.39e-06	0.000741	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.38e-06	0.000733	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.33e-06	0.000708	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.21e-06	0.000645	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—CD44—pancreatic cancer	1.08e-06	0.000574	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.05e-06	0.000562	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.04e-06	0.000557	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—GCG—pancreatic cancer	1.03e-06	0.00055	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—STK11—pancreatic cancer	9.71e-07	0.000517	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.11e-07	0.000485	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—TYMS—pancreatic cancer	8.35e-07	0.000445	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—APOE—pancreatic cancer	6.79e-07	0.000362	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.43e-07	0.000342	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	6.13e-07	0.000327	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PPARG—pancreatic cancer	5.92e-07	0.000315	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	5.39e-07	0.000287	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	4.7e-07	0.00025	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTGS2—pancreatic cancer	4.65e-07	0.000248	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PTEN—pancreatic cancer	4.06e-07	0.000216	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	2.86e-07	0.000153	CbGpPWpGaD
Methsuximide—CYP2C19—Metabolism—AKT1—pancreatic cancer	2.34e-07	0.000125	CbGpPWpGaD
